Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
The new patents cover critical advancements in cochlear implant technology
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
The NDA filing is supported by results from the phase III evERA Breast Cancer study
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe
Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
Subscribe To Our Newsletter & Stay Updated
